Hong Kong-listed Chinese biotech firm Jacobio Pharma says it hopes to commercialize a new drug that it's developing with AstraZeneca. Speaking on Bloomberg's "The China Show," the company's Co-CEO, Chief Medical Officer and Global Head of R&D Andrea Wang-Gillam discusses the significance of the Pan-KRAS inhibitor and her company's business outlook. (Source: Bloomberg)